Joseph Chen

TL;DR: Overall and intracranial antitumour activity of lorlatinib in patients with ALK-positive, advanced non-small-cell lung cancer and safety data for all treated patients (EXP1-6) are presented.

TL;DR: In this phase 1, dose-escalation study, lorlatinib showed both systemic and intracranial activity in patients with advanced ALK-positive or ROS1-positive NSCLC, most of whom had CNS metastases and had previously had two or more TKI treatments fail.

TL;DR: Lorlatinib, a potent ALK inhibitor, exerts unprecedented activity against neuroblastoma (NB) derived xenografts harboring common crizotinib-resistant ALK mutations, leading to a new window of opportunity for new treatments for NB patients.

TL;DR: The addition of a single dose of lorlatinib to daily dosing with rifampin significantly reduced lorLatinib plasma exposure relative to a single doses of lorbatinib administered alone and was associated with severe but self-limiting transaminase elevations in all healthy participants.

TL;DR: Co-administration of itraconazole and lorlatinib increased the plasma exposure of lor latinib relative to lorLatinib alone in healthy participants, and concomitant use of lorbatinib with strong CYP3A inhibitors should be avoided.